- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.70 Å
- Oligo State
- homo-hexamer
- Ligands
- 6 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 6 x VYE: (3S,5R)-5-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-N-(3-methylbutyl)piperidine-3-carboxamide(Non-covalent)
VYE.2: 16 residues within 4Å:- Chain A: Q.19, D.38, G.40, S.41, R.82, Y.83, S.84, T.85, P.118, F.119, F.124, V.127, I.137, D.226, G.228, A.229
13 PLIP interactions:13 interactions with chain A- Hydrophobic interactions: A:Q.19, A:D.38, A:Y.83, A:Y.83, A:V.127, A:I.137
- Hydrogen bonds: A:D.38, A:G.40, A:S.84, A:T.85
- Salt bridges: A:D.38
- pi-Stacking: A:F.124
- pi-Cation interactions: A:Y.83
VYE.4: 15 residues within 4Å:- Chain B: Q.19, V.36, D.38, G.40, S.41, Y.83, S.84, T.85, P.118, F.124, V.127, I.137, D.226, G.228, S.230
10 PLIP interactions:10 interactions with chain B- Hydrophobic interactions: B:V.36, B:Y.83, B:Y.83, B:V.127, B:I.137
- Hydrogen bonds: B:D.38, B:G.40, B:S.84, B:T.85
- Salt bridges: B:D.38
VYE.6: 16 residues within 4Å:- Chain C: Q.19, D.38, G.40, S.41, R.82, Y.83, S.84, T.85, P.118, F.119, F.124, V.127, I.137, D.226, G.228, A.229
13 PLIP interactions:13 interactions with chain C- Hydrophobic interactions: C:Q.19, C:D.38, C:Y.83, C:Y.83, C:V.127, C:I.137
- Hydrogen bonds: C:D.38, C:G.40, C:S.84, C:T.85
- Salt bridges: C:D.38
- pi-Stacking: C:F.124
- pi-Cation interactions: C:Y.83
VYE.8: 15 residues within 4Å:- Chain D: Q.19, V.36, D.38, G.40, S.41, Y.83, S.84, T.85, P.118, F.124, V.127, I.137, D.226, G.228, S.230
9 PLIP interactions:9 interactions with chain D- Hydrophobic interactions: D:V.36, D:Y.83, D:Y.83, D:V.127, D:I.137
- Hydrogen bonds: D:D.38, D:G.40, D:S.84
- Salt bridges: D:D.38
VYE.10: 16 residues within 4Å:- Chain E: Q.19, D.38, G.40, S.41, R.82, Y.83, S.84, T.85, P.118, F.119, F.124, V.127, I.137, D.226, G.228, A.229
13 PLIP interactions:13 interactions with chain E- Hydrophobic interactions: E:Q.19, E:D.38, E:Y.83, E:Y.83, E:V.127, E:I.137
- Hydrogen bonds: E:D.38, E:G.40, E:S.84, E:T.85
- Salt bridges: E:D.38
- pi-Stacking: E:F.124
- pi-Cation interactions: E:Y.83
VYE.12: 15 residues within 4Å:- Chain F: Q.19, V.36, D.38, G.40, S.41, Y.83, S.84, T.85, P.118, F.124, V.127, I.137, D.226, G.228, S.230
9 PLIP interactions:9 interactions with chain F- Hydrophobic interactions: F:V.36, F:Y.83, F:Y.83, F:V.127, F:I.137
- Hydrogen bonds: F:D.38, F:G.40, F:S.84
- Salt bridges: F:D.38
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Mori, Y. et al., Design and discovery of new (3S,5R)-5-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]piperidine-3-carboxamides as potent renin inhibitors. Bioorg.Med.Chem.Lett. (2012)
- Release Date
- 2012-12-19
- Peptides
- Renin: ABCDEF
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
AD
BE
AF
B
SMTL ID : 3vye.3 (2 other biounits)
Human renin in complex with inhibitor 7
Renin
Toggle Identical (ABCDEF)Related Entries With Identical Sequence
1bbs.1 | 1bbs.2 | 1bbs.3 | 1bbs.4 | 1rne.1 | 2bks.1 | 2bks.2 | 2bkt.1 | 2bkt.2 | 2iko.1 | 2iku.1 | 2il2.1 | 2ren.1 | 2v0z.1 | 2v0z.2 | 2v10.1 | 2v10.2 | 2v11.1 | 2v11.2 | 2v12.1 | 2v12.2 | 2v13.1 | 2v16.1 | 3g72.1 | 3g72.2 | 3g72.3 | 3oot.1 | 3oot.2 | 3oqf.1 | 3oqf.2 more...less...3oqk.1 | 3oqk.2 | 3q3t.1 | 3q3t.2 | 3q4b.1 | 3q4b.2 | 3q5h.1 | 3q5h.2 | 3sfc.1 | 3sfc.2 | 3sfc.3 | 3sfc.4 | 3sfc.5 | 3vsw.1 | 3vsw.2 | 3vsw.3 | 3vsw.4 | 3vsw.5 | 3vsx.1 | 3vsx.2 | 3vsx.3 | 3vuc.1 | 3vuc.2 | 3vuc.3 | 3vyd.1 | 3vyd.2 | 3vyd.3 | 3vye.1 | 3vye.2 | 3vyf.1 | 3vyf.2 | 3vyf.3 | 4gj5.1 | 4gj5.2 | 4gj6.1 | 4gj6.2 | 4gj7.1 | 4gj7.2 | 4gj8.1 | 4gj8.2 | 4gj9.1 | 4gj9.2 | 4gja.1 | 4gja.2 | 4gjb.1 | 4gjb.2 | 4gjc.1 | 4gjc.2 | 4gjd.1 | 4gjd.2 | 4pyv.1 | 4pyv.2 | 4q1n.1 | 4q1n.2 | 4q1n.3 | 4ryc.1 | 4ryc.2 | 4ryc.3 | 4ryg.1 | 4ryg.2 | 4ryg.3 | 4rz1.1 | 4rz1.2 | 4rz1.3 | 4s1g.1 | 4s1g.2 | 4s1g.3 | 4xx3.1 | 4xx3.2 | 4xx3.3 | 4xx3.4 | 4xx3.5 | 4xx4.1 | 4xx4.2 | 4xx4.3 | 4xx4.4 | 4xx4.5 | 5sy2.1 | 5sy2.2 | 5sy2.3 | 7xgk.1 | 7xgk.2 | 7xgo.1 | 7xgo.2 | 7xgp.1 | 7xgp.2